BiologicDrugReport
Biologic Drug Report
Your INDEPENDENT source of news about biologic drugs
 
Companies
Abbott
Amgen
Bayer
Biogen Idec
Bristol-Myers Squibb
Centocor
Chugai
Eli Lilly
Genentech
Genzyme
Imclone
Johnson & Johnson
Medarex
MedImmune
Merck Serono
Millennium
Novartis
Novo Nordisk
Organon
Ortho Biotech
Pfizer
Roche
Sanofi-Aventis
Schering-Plough
Wyeth
 
Biologic Drug Report - TNF Blockers
 

TNF blockers were the second largest selling class of biological products (excluding vaccines), with total sales in 2005 estimated at $7.64 billion.

Tumor Necrosis Factor (TNF) is a cytokine, a chemical substance which delivers messages between cells in the body, which is involved in the inflammatory process.

TNF blockers are part of a class of drugs known as Biologic Response Modifiers. They work by attaching to and impeding these chemical messengers, reducing inflammation and thus lessening pain.

The leading biologic TNF blockers are:

Name Company Class Use
Enbrel Amgen / Wyeth Fusion protein of Ig +sol TNF-R Treating rheumatoid arthritis and psoriasis
Remicade Centocor / J&J / Schering-Plough Recombinant chimeric mab Treating rheumatoid arthritis and psoriasis
Humira Amgen Recombinant fully human mab Treating rheumatoid arthritis and psoriasis

Advertising Policy
Privacy Policy | Terms and Disclaimers | About the Biologic Drug Report
Contact Us
Click to VerifyWe subscribe to the HONcode principles of the HON Foundation.

This is an independent news site reporting on Biologic Drugs. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.

Last Updated: 01/14/2007

(c) 2004-2007 Medical Week News, Inc. All Rights Reserved